Progress of interleukin-12 in treatment of solid tumors / 肿瘤研究与临床
Cancer Research and Clinic
;
(6): 627-630, 2022.
Article
in Chinese
| WPRIM
| ID: wpr-958904
ABSTRACT
Interleukin-12 (IL-12) is a pro-inflammatory cytokine derived from antigen-presenting cells. IL-12 has a variety of effector mechanisms such as promoting T cells proliferation and cytotoxicity, inducing T cells and NK cells to secrete interferon-γ (IFN-γ), etc. IL-12 shows significant anti-tumor effect in preclinical stage and is quickly used in clinic, but its systemic administration has serious dose-limiting toxicity. At present, most of the research is about the topical use of IL-12 to reduce systemic toxicity, change tumor microenvironment and activate immune system. This article reviews the research progress and clinical trials of IL-12 in the treatment of solid tumors in recent years.
Full text:
Available
Index:
WPRIM (Western Pacific)
Language:
Chinese
Journal:
Cancer Research and Clinic
Year:
2022
Type:
Article
Similar
MEDLINE
...
LILACS
LIS